Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173249 | 0.86 | PTGS2 (0.42) | PTGS2PTGS1 | |
| SCHEMBL4176750 | 0.83 | MAP2K4 (0.39) | HTTRAB9AL3MBTL1MAPTALOX15 | |
| SCHEMBL6234882 | 0.79 | PTGS2 (0.36) | PTGS2PTGS1SCDFADS1 | |
| SCHEMBL4174946 | 0.79 | MAPT (0.43) | PTGS2HTTRAB9AL3MBTL1MAPT | |
| SCHEMBL4181161 | 0.78 | KDR (0.38) | HTTMAPT | |
| SCHEMBL4185705 | 0.76 | DYRK1A (0.40) | PTGS1HTTRAB9AMAPT | |
| SCHEMBL4178035 | 0.76 | PDE5A (0.48) | PTGS2PTGS1RAB9AL3MBTL1MAPT | |
| SCHEMBL4173244 | 0.72 | PDE5A (0.52) | — | |
| SCHEMBL4179118 | 0.70 | MAP2K4 (0.37) | RAB9AMAPTALOX15 | |
| SCHEMBL4178043 | 0.69 | PTGS2 (0.38) | PTGS2PTGS1SCDFADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | PTGS2 1129/4885PTGS1 835/4885SCD 2874/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | PTGS2 1129/4885PTGS1 835/4885SCD 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.